Immunohistochemical expression of the stem cell marker CD133 in Carcinoma Colorectum
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
Background
Colorectal carcinoma is a major contributor to cancer-related morbidity and mortality, with rising incidence in the Indian population. Conventional prognostic assessment based on histological grade and TNM staging is increasingly supplemented by molecular markers that may improve prognostication and therapeutic targeting. CD133 (Prominin-1), a cancer stem cell marker, has been reported to correlate with clinicopathological features, prognosis, and resistance to therapy in colorectal carcinoma, although Indian data remain limited.
Research Question
Does immunohistochemical expression of CD133 in colorectal adenocarcinoma demonstrate prognostic value when correlated with established clinicopathological parameters such as tumor grade, lymphovascular invasion, tumor stage, nodal stage, and TNM stage?
Methodology
This study is designed as an observational study with prospective and retrospective recruitment over a two-year period (May 2025–April 2027). Histopathologically confirmed cases of colorectal adenocarcinoma from biopsy or surgical specimens will be included, with an estimated sample size of approximately 40 patients. Clinical, radiological, and pathological data will be collected, followed by routine histopathology and immunohistochemical staining for CD133. Expression will be quantitatively and qualitatively scored and correlated with clinicopathological variables using appropriate statistical tests (Student’s t-test, ANOVA, and Chi-square) through SPSS software.
Conclusion
The study aims to determine whether CD133 expression can serve as a prognostic and predictive biomarker in colorectal carcinoma, potentially aiding in risk stratification, therapeutic decision-making, and assessment of treatment resistance.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 90.00 Year(s)（—）
- 性别
- All
入选标准
- •Biopsy diagnosed carcinoma colorectum.
- •The patients diagnosed as carcinoma colorectum on surgically resected specimen.
- •The patients with the histological diagnosis of adenocarcinoma irrespective of the grade of the tumour.
- •The patients having adequate clinical details in regards of the adenocarcinoma colorectum.
排除标准
- •The patients histopathologically diagnosed of cancer of colorectum other than adenocarcinoma.
- •The patients having inadequate clinical details pertaining to histopathological diagnosis.
- •The patients having tumour tissue blocks which are inadequate to be processed for CD133 immunostaining.
研究者
Dr Sanket Pawar
Datta Meghe Institute of Higher Education and Research (DMIHER)